- Home
- ALZN vs LCFY Comparison
ALZN vs LCFY Comparison
Compare ALZN & LCFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALZN
- LCFY
- Stock Information
- Founded
- ALZN 2016
- LCFY 2009
- Country
- ALZN United States
- LCFY Australia
- Employees
- ALZN N/A
- LCFY N/A
- Industry
- ALZN Medicinal Chemicals and Botanical Products
- LCFY
- Sector
- ALZN Health Care
- LCFY
- Exchange
- ALZN Nasdaq
- LCFY Nasdaq
- Market Cap
- ALZN 9.0M
- LCFY 9.2M
- IPO Year
- ALZN 2021
- LCFY 2022
- Fundamental
- Price
- ALZN $2.32
- LCFY $3.32
- Analyst Decision
- ALZN Strong Buy
- LCFY
- Analyst Count
- ALZN 1
- LCFY 0
- Target Price
- ALZN $42.00
- LCFY N/A
- AVG Volume (30 Days)
- ALZN 100.6K
- LCFY 20.3K
- Earning Date
- ALZN 12-11-2025
- LCFY 11-12-2025
- Dividend Yield
- ALZN N/A
- LCFY N/A
- EPS Growth
- ALZN N/A
- LCFY N/A
- EPS
- ALZN N/A
- LCFY N/A
- Revenue
- ALZN N/A
- LCFY $2,099,713.00
- Revenue This Year
- ALZN N/A
- LCFY N/A
- Revenue Next Year
- ALZN N/A
- LCFY N/A
- P/E Ratio
- ALZN N/A
- LCFY N/A
- Revenue Growth
- ALZN N/A
- LCFY N/A
- 52 Week Low
- ALZN $2.06
- LCFY $2.51
- 52 Week High
- ALZN $12.87
- LCFY $13.98
- Technical
- Relative Strength Index (RSI)
- ALZN 45.72
- LCFY 19.33
- Support Level
- ALZN $2.21
- LCFY $3.80
- Resistance Level
- ALZN $2.61
- LCFY $3.97
- Average True Range (ATR)
- ALZN 0.16
- LCFY 0.26
- MACD
- ALZN -0.01
- LCFY -0.03
- Stochastic Oscillator
- ALZN 32.29
- LCFY 10.16
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
About LCFY Locafy Limited
Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.